Eliana Saul Furquim Werneck Abdelhay

Dr. Eliana Saul Furquim Werneck Abdelhay

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 January 2018 in Genes
Verified
Journal Article
Open access
PDF file
BPBruno R. B. Pires
Bruno R. B. Pires
Rafael Cardoso Maciel Costa SilvaRafael Cardoso Maciel Costa Silva
Rafael Cardoso Maciel Costa Silva
GFGerson Moura Ferreira
Gerson Moura Ferreira
EAEliana Saul Furquim Werneck Abdelhay
Eliana Saul Furquim Werneck Abdelhay
Nuclear Factor-kappa B (NF-κB) is a transcription factor family that regulates a large number of genes that are involved in important physiological processes, including survival, inflammation, and immune responses. More recently, constitutive expression of NF-κB has been associated with several types of cancer. In addition, microorganisms, such as viruses and bacteria, cooperate in the activation of NF-κB in tumors, confirming the multifactorial role of this transcription factor as a cancer driver. Recent reports have shown that the NF-κB signaling pathway should receive attention for the development of therapies. In addition to the direct effects of NF-κB in cancer cells, it might also impact immune cells that can both promote or prevent tumor development. Currently, with the rise of cancer immunotherapy, the link among immune cells, inflammation, and cancer is a major focus, and NF-κB could be an important regulator for the success of these therapies. This review discusses the contrasting roles of NF-κB as a regulator of pro- and antitumor processes and its potential as a therapeutic target.

17 April 2021 in Genes
Verified
Journal Article
Open access
PDF file
IPIgor Petrone
Igor Petrone
PBPaula Sabbo Bernardo
Paula Sabbo Bernardo
ESEverton Cruz dos Santos
Everton Cruz dos Santos
EAEliana Saul Furquim Werneck Abdelhay
Eliana Saul Furquim Werneck Abdelhay
Folate (vitamin B9) is found in some water-soluble foods or as a synthetic form of folic acid and is involved in many essential biochemical processes. Dietary folate is converted into tetrahydrofolate, a vital methyl donor for most methylation reactions, including DNA methylation. 5,10-methylene tetrahydrofolate reductase (MTHFR) is a critical enzyme in the folate metabolism pathway that converts 5,10-methylenetetrahydrofolate into 5-methyltetrahydrofolate, which produces a methyl donor for the remethylation of homocysteine to methionine. MTHFR polymorphisms result in reduced enzyme activity and altered levels of DNA methylation and synthesis. MTHFR polymorphisms have been linked to increased risks of several pathologies, including cancer. Breast cancer, gliomas and gastric cancer are highly heterogeneous and aggressive diseases associated with high mortality rates. The impact of MTHFR polymorphisms on these tumors remains controversial in the literature. This review discusses the relationship between the MTHFR C677T and A1298C polymorphisms and the increased risk of breast cancer, gliomas, and gastric cancer. Additionally, we highlight the relevance of ethnic and dietary aspects of population-based studies and histological stratification of highly heterogeneous tumors. Finally, this review discusses these aspects as potential factors responsible for the controversial literature concerning MTHFR polymorphisms.

28 July 2012 in BMC Bioinformatics
Verified
Journal Article
Open access
PDF file
AMAmanda M Maia
Amanda M Maia
JSJoão Hm da Silva
João Hm da Silva
AMAndré L Mencalha
André L Mencalha
ECErnesto Raul Caffarena
Ernesto Raul Caffarena
EAEliana Saul Furquim Werneck Abdelhay
Eliana Saul Furquim Werneck Abdelhay
Human TWIST1 is a highly conserved member of the regulatory basic helix-loop-helix (bHLH) transcription factors. TWIST1 forms homo- or heterodimers with E-box proteins, such as E2A (isoforms E12 and E47), MYOD and HAND2. Haploinsufficiency germ-line mutations of the twist1 gene in humans are the main cause of Saethre-Chotzen syndrome (SCS), which is characterized by limb abnormalities and premature fusion of cranial sutures. Because of the importance of TWIST1 in the regulation of embryonic development and its relationship with SCS, along with the lack of an experimentally solved 3D structure, we performed comparative modeling for the TWIST1 bHLH region arranged into wild-type homodimers and heterodimers with E47. In addition, three mutations that promote DNA binding failure (R118C, S144R and K145E) were studied on the TWIST1 monomer. We also explored the behavior of the mutant forms in aqueous solution using molecular dynamics (MD) simulations, focusing on the structural changes of the wild-type versus mutant dimers.

Verified
Journal Article
Open access
PDF file
EVEmylli D. Virginio
Emylli D. Virginio
PKPaula Helena Kubitschek-Barreira
Paula Helena Kubitschek-Barreira
Marjorie Vieira BatistaMarjorie Vieira Batista
Marjorie Vieira Batista
MSMarcelo R. Schirmer
Marcelo R. Schirmer
EAEliana Saul Furquim Werneck Abdelhay
Eliana Saul Furquim Werneck Abdelhay
LLLeila Lopes-Bezerra
Leila Lopes-Bezerra
Invasive aspergillosis is a life-threatening lung or systemic infection caused by the opportunistic mold Aspergillus fumigatus. The disease affects mainly immunocompromised hosts, and patients with hematological malignances or who have been submitted to stem cell transplantation are at high risk. Despite the current use of Platelia™ Aspergillus as a diagnostic test, the early diagnosis of invasive aspergillosis remains a major challenge in improving the prognosis of the disease. In this study, we used an immunoproteomic approach to identify proteins that could be putative candidates for the early diagnosis of invasive aspergillosis. Antigenic proteins expressed in the first steps of A. fumigatus germination occurring in a human host were revealed using 2-D Western immunoblots with the serum of patients who had previously been classified as probable and proven for invasive aspergillosis. Forty antigenic proteins were identified using mass spectrometry (MS/MS). A BLAST analysis revealed that two of these proteins showed low homology with proteins of either the human host or etiological agents of other invasive fungal infections. To our knowledge, this is the first report describing specific antigenic proteins of A. fumigatus germlings that are recognized by sera of patients with confirmed invasive aspergillosis who were from two separate hospital units.

7 February 2023 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
BPBruno de Paula
Bruno de Paula
RKRosalind Kieran
Rosalind Kieran
SKSamantha Shui Yuan. Koh
Samantha Shui Yuan. Koh
SCSusanne Cancer Crocamo
Susanne Cancer Crocamo
EAEliana Saul Furquim Werneck Abdelhay
Eliana Saul Furquim Werneck Abdelhay
DMDaniel Muñoz-Espín
Daniel Muñoz-Espín
Triple-negative breast cancer (TNBC) is associated with an elevated risk of recurrence and poor prognosis. Historically, only chemotherapy was available as systemic treatment, but immunotherapy and targeted therapies currently offer prolonged benefits. TNBC is a group of diseases with heterogeneous treatment sensitivity, and resistance is inevitable and early for a large proportion of the intrinsic subtypes. Although senescence induction by anticancer therapy offers an immediate favorable clinical outcome once the rate of tumor progression reduces, these cells are commonly dysfunctional and metabolically active, culminating in treatment-resistant repopulation associated with worse prognosis. This heterogeneous response can also occur without therapeutic pressure in response to damage or oncogenic stress, playing a relevant role in the carcinogenesis. Remarkably, there is preclinical and exploratory clinical evidence to support a relevant role of senescence in treatment resistance. Therefore, targeting senescent cells has been a scientific effort in many malignant tumors using a variety of targets and strategies, including increasing proapoptotic and decreasing antiapoptotic stimuli. Despite promising results, there are some challenges to applying this technology, including the best schedule of combination, assessment of senescence, specific vulnerabilities, and the best clinical scenarios. This review provides an overview of senescence in TNBC with a focus on future-proofing senotherapy strategies.

1 January 2012 in Cytotherapy
Verified
Journal Article
Closed access
BRBárbara Du Rocher
Bárbara Du Rocher
AMAndre Luiz Mencalha
Andre Luiz Mencalha
BGBernadete Evangelho Gomes
Bernadete Evangelho Gomes
EAEliana Saul Furquim Werneck Abdelhay
Eliana Saul Furquim Werneck Abdelhay